Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    BRCA1 transcriptional induction (2–4Γ—) in epithelial EcR-293 cells shifts a reproducible microarray program (373 consistently altered genes), including repression of estrogen-response/cell-cycle drivers (e.g., MYC, CCND1) and upregulation of cytokine/IFN-related genes (e.g., STAT1, JAK1) and extracellular-matrix/secreted markers (e.g., LAMA3, STC1). The paper further reports coordinated protein expression in primary breast/ovarian tumors for BRCA1 with ID4 (stronger in breast than ovarian) and with STC1 (strong correlation in breast, weaker in ovarian), supporting the idea of transcriptional coupling to breast tumorigenesis-associated phenotypes ().



     Long Explanation


    Paper: β€œBRCA1 transcriptionally regulates genes involved in breast tumorigenesis”
    Proceedings of the National Academy of Sciences (2002). Focus: how BRCA1 transcriptional regulation links to tumor suppression programs in epithelial cells and correlates with primary tumor protein expression.
    Open DOI Β· Last updated: 2026-04-16
    What the paper does (evidence-based)
    • Creates an inducible BRCA1 system in EcR-293 epithelial cells (pIND-BRCA1), inducing BRCA1 to roughly 2–4Γ— endogenous levels using ponasterone A. ()
    • Runs microarrays across six paired replicate experiments and applies a tiered statistical/robustness filter, yielding 373 genes consistently altered and 62 genes with β‰₯2-fold change. ()
    • Highlights mechanistically plausible tumor-relevant nodes: repression of CCND1 and MYC (estrogen-responsive/cell-cycle drivers), induction of JAK1/STAT1 (cytokine/IFN signaling), and changes in extracellular matrix/secreted factors including LAMA3 and STC1. ()
    • Validates transcription–protein coordination in primary tumors by immunohistochemistry for BRCA1 with ID4 and STC1 in a cohort of 168 sporadic breast/ovarian tumors. ()
    Visual 1: Example fold-change effects reported for selected targets
    Bars are the paper’s reported fold-changes (microarray expression changes) for prominent highlighted genes.
    Source: selected gene fold-changes as described in the paper text/abstract. ()
    Visual 2: Reported protein-expression coordination in primary tumors
    The paper reports correlation coefficients for BRCA1 vs ID4 and BRCA1 vs STC1 separately in breast and ovarian tumors.
    Source: IHC correlation statements in the paper (BRCA1–ID4 and BRCA1–STC1). ()
    Skeptical methods audit (what supports causality vs correlation)
    Strengths
    • Inducible BRCA1 with modest expression: Induction is characterized by Western blot and set to ~2–4Γ— endogenous levels, and the authors explicitly note that this level does not stimulate apoptosis over the induction/growth window, reducing (but not eliminating) confounding from massive overexpression artifacts. ()
    • Replication + robustness filtering: Six paired replicate experiments and a simulation-based consistency filter are used to retain genes (373) that remain consistently significant beyond random noise assumptions. ()
    • Directionally tumor-relevant gene sets: The highlighted changes map onto cancer-related transcriptional logic the paper discusses (MYC/CCND1 repression; STAT1/JAK1 induction; ECM/secreted factor modulation). ()
    Limitations / β€œknown unknowns”
    • Cell-line context: The transcriptional program is measured in EcR-293 (kidney epithelial) with induced BRCA1; this is a controlled system but not breast/ovarian lineage, so lineage-specific transcriptional wiring may differ. The authors note they chose this noncancerous epithelial line and explain why BRCA1-null breast/ovarian epithelial models were not feasible at the time. ()
    • Moderate induction reduces apoptosis confounding but does not prove direct transcriptional targets: Microarrays show expression changes; they do not, in the provided excerpt, include direct evidence (e.g., promoter occupancy) that each gene is a primary BRCA1 transcriptional target rather than downstream secondary response. ()
    • IHC correlation is not mechanism: Correlation between BRCA1 and ID4/STC1 supports transcriptional coupling, but alternative explanations include shared upstream regulators or selection effects in tumor tissue. (Correlation nature is explicitly stated by rΒ²/P values; mechanistic causality is not established in the provided text.) ()
    • Statistical filter depends on modeling assumptions: Their simulation uses an SD=29 for background intensity (stated as background for the HuGeneFL arrays). If noise structure differs from the assumption, some marginal probes could be missed or included. ()
    Mechanistic themes the paper emphasizes (what is supported vs what is proposed)
    1) Estrogen-response / cell-cycle control
    The paper reports BRCA1 induction reduces CCND1 (>3-fold) and MYC (~4.2-fold), and it frames these changes as consistent with BRCA1 repressing estrogen-receptor–linked transcriptional programs in ER-positive contexts. ()
    2) Cytokine/IFN-related pro-growth control
    The paper reports induction of STAT1 (~2.5-fold) and JAK1 (~2.4-fold) and proposes a growth-inhibitory logic through IFN-Ξ³ / STAT1 activation and downstream anti-proliferative programs (including a smaller but significant effect on p21). ()
    3) Extracellular matrix and secreted marker coupling
    The paper emphasizes increased expression of LAMA3 (~2-fold) and strong association/regulation of the secreted prohormone STC1 (~2-fold induction by BRCA1) in a way that correlates with BRCA1 in primary breast/ovarian tumors. ()
    BGPT β€œepistemic humility” checklist
    • Known: The paper reports inducible BRCA1 β†’ reproducible microarray expression changes (373 genes), and reports IHC correlations with ID4 and STC1 in primary tumors. ()
    • Inferred: The paper’s mechanistic narratives (e.g., ER suppression logic, STAT1/IFN growth inhibition, ECM/secreted marker roles) are plausible interpretations but are not directly demonstrated by target occupancy or perturbation hierarchy in the provided text. ()
    • Uncertain / disprovable next steps: Determine primary vs secondary targets (direct binding/Pol II occupancy), test lineage specificity (breast/ovarian epithelial models), and causally validate whether ID4/STC1 regulation contributes to tumor phenotypes rather than correlating with BRCA1 loss. (These are logical next-step statements based on what the paper measures vs what it has not measured in the excerpt.) ()
    Author reviews (BGPT)


    Feedback:    

    Updated: April 17, 2026

     BGPT Paper Review


    Study Novelty

    70%

    Moderately novel for its era: it links BRCA1 to a specific transcriptional program in an inducible epithelial system and highlights candidate tumor-relevant regulators/markers (e.g., MYC/CCND1, STAT1/JAK1, LAMA3, STC1) with primary tumor IHC correlations, but the general concept that BRCA1 affects transcription was already supported by prior work the paper cites internally. ()


    Scientific Quality

    70%

    Good experimental control via inducible, modest BRCA1 expression and replication with a robustness-filtering strategy, plus tumor IHC correlation. However, for the mechanistic claims, the excerpt indicates reliance on expression changes and correlation rather than direct chromatin occupancy or causal perturbation hierarchies for each highlighted gene, and the model lineage is not breast/ovarian epithelium. ()


    Study Generality

    60%

    Specific to epithelial transcriptional programs and to tissue-connection via tumor-marker correlations; lineage specificity and direct-target uncertainty limit generalization beyond the tested system. ()


    Study Usefulness

    70%

    Useful as a foundation for candidate BRCA1-regulated tumor-associated transcriptional markers and pathways; its practical value is in generating a constrained target set (373 genes; 62 β‰₯2-fold) and proposing STC1/LAMA3/STAT1/JAK1/CCND1/MYC/ID4 as follow-up nodes. ()


    Study Reproducibility

    60%

    Moderate: the inducible system and microarray platform are described, and the gene list is obtained via an explicit statistical robustness procedure, but no deposited raw expression matrix is explicitly accessible in the provided excerpt and the details of downstream validation beyond IHC are not exhaustive here. ()


    Explanatory Depth

    60%

    Mechanistic depth is moderate: the paper provides plausible pathway narratives connecting BRCA1 induction to estrogen/cell-cycle repression, cytokine/IFN signaling induction, and ECM/secreted marker changes, but direct mechanistic causality (e.g., direct promoter binding for each key gene) is not established in the excerpted content. ()


    🎁 Authors: Collect 148 Free Science Tokens (β‰ˆ $14.8 USD)

    Claim My Author Tokens

    Use for 37 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $14.8 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Reconstruct the paper’s highlighted BRCA1 response signature by organizing the reported gene-direction set, then compute pathway-level overrepresentation scores using curated gene sets for tumorigenesis, cytokine/IFN, and ECM programs.



     Hypothesis Graveyard


    A simple β€œBRCA1 always drives apoptosis” model is unlikely to fit this paper’s core system because BRCA1 induction at ~2–4Γ— did not stimulate apoptosis/growth inhibition in the described window, implying that the transcriptional program can be tumor-relevant without overt apoptosis in that context. ()


    β€œOvarian and breast should show equal BRCA1-marker coupling strength” is inconsistent with their reported tissue differences (stronger BRCA1–ID4 and BRCA1–STC1 correlations in breast than ovarian). ()

     Science Art


    Paper Review: BRCA1 transcriptionally regulates genes involved in breast tumorigenesis Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending